European Respiratory Society

Shaping lung health from the start: early-life trajectories and lifelong risk ExtractIn their landmark study of the natural history of chronic airflow obstruction among London working men, Fletcher and Peto [1] identified two factors leading to impaired lung function in later life. The first and most important was cigarette smoki...

European Respiratory Journal: Life-course trajectories of lung function are established in childhood, but show considerable potential for improvement in the first years of life https://publications.ersnet.org/content/erj/67/3/2502359

ERJ Open Research: The STAT3 pathway is activated in the COPD airway epithelium and promotes epithelial-to-mesenchymal transition in an IL-6-dependent manner https://bit.ly/46RKYpk

A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease ExtractPulmonary hypertension (PH) frequently develops among patients with interstitial lung disease (ILD) and leads to a markedly worsened prognosis (14% survival at 5 years) [1] and increased morbidity [2, 3]. Despite its high prevalence in ILD (10–20...

European Respiratory Journal: A normal BNP has a poor negative predictive value in ruling out pulmonary hypertension in interstitial lung disease. Relying on an elevated BNP for detection of PH in ILD may falsely reassure clinicians. https://bit.ly/3OW3gia

ABSTRACT SUBMISSION DEADLINE EXTENDED TO 19 MARCH – There is still time to submit your research for inclusion in the ERS Respiratory Impact Conference – an event focusing on real-world implementation (of scientific advances, guidelines & policy) https://channel.ersnet.org/hp-187-1-abstracts

ERJ Open Research: 4.5% of 292 COPD patients experienced an acute decrease in lung function at 2 h following an oral 1.25 mg dose of the cardioselective β-blocker bisoprolol. A further 2.1% experienced systolic blood pressure decrease below 100 mmHg. https://bit.ly/4miPS3y

European Respiratory Journal: This research letter describes for the first time a case of hypoxaemia secondary to intrapulmonary vascular dilatation in a patient treated with luspatercept, which was reversible when treatment was discontinued https://bit.ly/3Kv2uHa

New Interactive Education video available: Mastering progressive pulmonary fibrosis – bridging specialities for holistic care!

Join the experts as they address education gaps in the diagnosis and management of progressive pulmonary fibrosis.

Watch now: https://bit.ly/4dji0BA

ERJOR: Tailored pulmonary rehabilitation for α1-ATD is vital. Flexible, patient-centred programmes including personalised exercise, streamlined referrals and structured follow-up can overcome α1-ATD's unique challenges and improve long–term outcomes. https://bit.ly/4fPG2DR

ERJ: Severe asthma is linked to a significantly higher mortality risk, mainly from respiratory causes, compared to mild-to-moderate asthma. T2 inflammation may contribute to the risk, highlighting the need for early identification and targeted management. https://bit.ly/4nfTy5J

European Respiratory Journal: Fan-to-face therapy is a simple, feasible, low-cost, low-resource nonpharmacological approach to reduce exertional breathlessness during exercise training in adults with chronic lung disease https://bit.ly/4oMpcbX

As ERS Vice President Arzu Yorgancıoğlu reminds us, the health and science communities have a responsibility to make reliable information accessible. Help us #DefendScience and #ProtectHealth – download and share campaign resources in eight languages: https://bit.ly/4aABqjG

ERJ Open Research: A case of ulcerative colitis-associated bronchiectasis relapse after lung transplantation, with new bronchiectasis and inflammatory airway infiltrates of recipient origin, confirmed by chimaerism analysis and immune repertoire studies https://bit.ly/42z1BDh

Defend Science, Public Health - Campaign - ERS and ELF Science is under attack. Disinformation, political pressure and funding cuts risk undermining years of progress in medical research. Support our campaign.

@europarl.europa.eu has called for action on health disinformation, health funding and stronger cooperation with health professionals and researchers — what ERS has been raising in our #DefendScience #ProtectHealth campaign.

Help keep up the pressure: ersnet.org/advocacy/campaign-defend-science

The deadline to apply for an ERS Clinical Training Fellowship is just under one month away.

Don’t miss this opportunity to conduct a project and explore clinical skills and procedures at an institution outside of your home country.

Apply now: https://bit.ly/45gdu1d

New Coffee Talk available ☕

In this episode Prof. Mona Bafadhel catches up with Prof. Wim Janssens and Associate Prof. Neil Greening to discuss the use of BAt (Baseline, acuity and trigger model) to classify COPD exacerbations.

Watch now: https://bit.ly/4layONf

Bronchodilation response, respiratory burden and biomarkers: insights from impulse oscillometry and spirometry ExtractThe bronchodilator response (BDR) test is commonly used in asthma diagnosis workflow and is typically assessed through spirometry. A positive BDR test supports the diagnosis when clinical suspicion of asthma exists. However, other methods, such a...

ERJOR: Participants with BDR in both IOS and FEV₁ have the highest prevalence of symptoms, asthma, COPD and inflammation, highlighting the added value of combining these methods to assess bronchodilator responsiveness and peripheral airway dysfunction: https://bit.ly/4b3R6Ly

Patient-reported dyspnoea documented by nurses twice a day predicts up to 6-fold increased in-hospital mortality and 2-fold increased yearly mortality in the following 2 years. Documentation takes <1 min and provides a tool to identify patients at risk. https://bit.ly/4g9xw2z

Factors affecting clinical trial participation in people with interstitial lung disease: a qualitative study BackgroundClinical trials are the best method for evaluating new treatments for people with interstitial lung disease (ILD). However, recruitment in ILD clinical trials is often challenging. Certain trial characteristics may influence willingness to par...

Perceived impact on current health plays a central role in the decision to participate in clinical trials along with concerns about life disruption and financial burden. People with ILD value support, clear communication and post-trial feedback. https://bit.ly/4sicmUL

One week left to apply!

The call for applications to join the ERS Clinical Practice Guidelines Methodology Network will close soon. This unique training opportunity gives early career members the skills needed to produce high-quality guidelines.

Find out more: https://bit.ly/4jPX8TP

All eosinophilic granulomatosis with polyangiitis (EGPA) disease phase subgroups have substantial disease burden; the vasculitic subgroup has more severe disease. Biologics may reduce corticosteroid use and improve EGPA control in a real-world setting. https://bit.ly/45HyeQQ

There is just one month left to apply for an ERS Short-Term Research Fellowship.

Don’t miss this opportunity to conduct a project and explore research techniques at an institution outside of your home country.

Apply now: https://bit.ly/47jNJzA

Bronchiectasis in children: a systematic review of cytokine profile, immune cell phenotypes and microbiota in bronchoalveolar lavage fluid BackgroundPaediatric noncystic fibrosis bronchiectasis (NCFB) is a chronic respiratory condition characterised by airway infection, chronic inflammation, mucociliary dysfunction and structural lung damage. Emerging evidence highlights the importance of ...

Neutrophilic inflammation, amplified by dysregulated cytokine responses, possibly sustained by microbial dysbiosis, appears central to paediatric NCFB. Key gaps include roles of dysbiosis, adaptive immunity, immune trajectories and lesser-known pathways. https://bit.ly/4aW3xsP

Assessment and management of post-COVID-19 pulmonary complications: a rapid review The rising global prevalence of post-COVID-19 condition (PCC) underscores the substantial and ongoing burden faced by individuals following severe acute respiratory syndrome coronavirus 2 infection. The volume of emerging evidence regarding pulmonary-re...

For pulmonary-related post-COVID-19 condition thorough assessment is recommended to rule out other conditions. Growing evidence supports multidisciplinary rehabilitation for management, while evidence for pharmacological treatments remains limited. https://bit.ly/4l0m7EK

Physical inactivity in chronic airways disease: an important candidate in the treatable traits paradigm BackgroundPhysical inactivity is a common and potentially modifiable trait in individuals with chronic airways disease, yet disease-specific physical activity profiles and clinical determinants remain poorly defined.MethodsWe conducted a systematic revi...

European Respiratory Review: Physical inactivity is highly prevalent across chronic airways diseases and demonstrates the key features of a clinically relevant treatable trait. https://publications.ersnet.org/content/errev/35/179/250165

The impact of elexacaftor–tezacaftor–ivacaftor on cardiometabolic risk factors: a systematic review Elexacaftor–tezacaftor–ivacaftor (ETI) is a highly effective modulator therapy associated with significant improvements in respiratory function and quality of life among people living with cystic fibrosis (CF). However, ETI has also been shown to result...

European Respiratory Review: Increasing life expectancy in cystic fibrosis, in addition to the use of highly effective modulator treatments, may introduce increased risk of traditional cardiometabolic risk factors that warrant clinical surveillance. https://bit.ly/4aTtxVH

ERJ: In PAH patients, four phenotypes of RA and RV dilatation could be identified. In particular, patients with both RA and RV dilatation have a worse prognosis than patients with sole RV dilatation, but were only distinguishable through cardiac imaging. https://bit.ly/47S9eHW

Young people often get health information from social media influencers, not health professionals. Susanne Vijverberg, ERS Representative to EMA, explains why we need to meet the next generation where they are.

Help us #DefendScience and #ProtectHealth: https://bit.ly/4aABqjG

ERJ Podcast February 2026: Addressing the global challenges of COPD and asthma As part of the February issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews David Halpin (University of Exeter Medical School,

The ERJ presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews David Halpin about his Viewpoint editorial on a shared vision from GOLD and GINA of how to address the global challenges of COPD and asthma: https://bit.ly/46gBjYg

The next instalment of ERS Vision Live, co-chaired by Dr Janice Leung and Prof. Des Cox, will focus on cannabis, vaping and tobacco in the 21st century.

📆 10 March (18:00–19:00 CET)
📍 Online

Learn more and register your free place: https://bit.ly/4aROvEa

ONLY 1 WEEK LEFT: Don’t miss the 5 March deadline to submit your abstract for the ERS Respiratory Impact Conference 2026. We welcome abstracts related to any aspect of health service delivery, applied & implementation science, & quality improvement initiatives: https://bit.ly/4afb9Yh